Exelixis Signs an Exclusive Option and License Agreement with Iconic Therapeutics for Advancing ADC Program
Shots:
- Iconic to receive $7.5M upfront- funds for preclinical development and is eligible for option exercise payment- development- regulatory & commercial milestones- royalties on sales. Exelixis to get an option to license Iconic’s ICON-2 ADC program and will exercise its option at IND filing
- The focus of the collaboration is to robust Exelixis’s oncology portfolio by developing therapies utilizing Iconic’s Tissue Factor antibody expertise
- ICON-2 is a second-generation ADC targeting Tissue Factor in solid tumors as TF overexpression accelerates angiogenesis- metastasis leading to tumor development and progression
Ref: Exelixis | Image: Iconic Therapeutics
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com